QRG Capital Management Inc. Sells 658 Shares of IQVIA Holdings Inc. (NYSE:IQV)

QRG Capital Management Inc. cut its position in IQVIA Holdings Inc. (NYSE:IQV) by 10.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,532 shares of the medical research company’s stock after selling 658 shares during the quarter. QRG Capital Management Inc.’s holdings in IQVIA were worth $1,087,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. US Bancorp DE grew its stake in IQVIA by 62.2% in the 3rd quarter. US Bancorp DE now owns 27,061 shares of the medical research company’s stock valued at $6,413,000 after buying an additional 10,379 shares in the last quarter. Farther Finance Advisors LLC grew its position in shares of IQVIA by 35.2% in the third quarter. Farther Finance Advisors LLC now owns 407 shares of the medical research company’s stock valued at $96,000 after purchasing an additional 106 shares in the last quarter. Chicago Partners Investment Group LLC bought a new stake in shares of IQVIA during the 3rd quarter valued at $218,000. Optas LLC purchased a new stake in IQVIA during the 3rd quarter worth about $210,000. Finally, Conning Inc. bought a new position in IQVIA in the 3rd quarter worth about $206,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

IQV has been the topic of several analyst reports. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Robert W. Baird decreased their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. UBS Group cut their price target on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 7th. Bank of America decreased their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Finally, Stifel Nicolaus dropped their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Four investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $251.22.

IQVIA Stock Down 2.2 %

Shares of NYSE IQV opened at $184.67 on Tuesday. The stock has a market capitalization of $32.52 billion, a P/E ratio of 24.62, a PEG ratio of 1.99 and a beta of 1.48. IQVIA Holdings Inc. has a one year low of $184.06 and a one year high of $261.73. The firm’s 50 day simple moving average is $198.84 and its two-hundred day simple moving average is $214.25. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.